NeoStem Moves Toward Overcoming Limitations in Stem Cell Therapy Development

| About: Caladrius Biosciences, (CLBS)

NeoStem, Inc. (NBS) announced a stem cell collaboration with ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. [OTCBB: IRBS]. NeoStem will investigate whether Homspera, ImmuneRegen’s lead product, will enhance stem cell activity when used in combination with NeoStem's VSEL technology.

NeoStem holds an exclusive license for very small embryonic-like stem cells (VSELs), which are found in the bone marrow and can be harvested from the peripheral blood of adults. According to NeoStem, it is the first company to provide adult stem cell collection and banking for adults. NeoStem is also conducting R&D on adult stem cells, including VSEL-based therapies, for regenerative purposes in the US and China.

ImmuneRegen has said Homspera seems to aid differentiation of human adult stem cells, particularly into hematopoietic stem cells that can become blood cells and form the foundation of the body's immune system. Like hematopoietic stem cells, VSELs are also found in adults, but may have broader applications and are morphologically closer to embryonic stem cells in their potential.

NeoStem harvests very small embryonic-like stem cells from individual patients, representing a significant step toward overcoming two current limitations in the development of stem cell therapies: the ethical dilemma surrounding embryonic stem cells, and the immunological problems associated with using cells from a donor.

Under the terms of the collaboration, NeoStem has the right to execute an option agreement to negotiate an exclusive license to resulting technology.

NeoStem is building of a network of adult stem cell collection centers in the US and China. NeoStem owns a majority position in Suzhou Erye, which manufactures and distributes generic antibiotics in China.

Disclosure: none.